Table 1 Study characteristics with placebo.
Author/year | Country | Case number (probiotics/placebo) | Diagnostic Methods | Probiotics composition | Eradication Therapy | % Eradication in ITT (probiotics/placebo) | % Eradication in PP (probiotics/placebo) | Review of H. pylori |
|---|---|---|---|---|---|---|---|---|
Nista et al.22 | Italy | 120 (60/60) | 13C-UBT | Bacillus clausii (B. clausii) | (rabeprazole 20 mg bid + clarithromycin 500 mg bid + amoxicillin 1 g bid) × seven days + (probiotics or placebo) × 14 days | 72.22/71.15 | 78/74 | 13C-UBT six weeks after the end of treatment. |
Navarro- Rodriguez et al.21 | Brazil | 107 (55/52) | 13C-UBT or histology | Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum and Streptococcus faecium | (lansoprazole 30 mg bid + tetracycline 500 mg bid + furazolidone 200 mg bid) × seven days + (probiotics or placebo) × 30 days | 81.82/76.92 | 88.24/81.63 | 13C-UBT eight weeks after the end of treatment. |
Cremonini et al.18 | Italy | 42 (21/21) | 13C-UBT | Lactobacillus GG and S. boulardii | (rabeprazole 20 mg bid + clarithromycin 500 mg bid + tinidazole 500 mg bid) x seven days + (probiotics or placebo) × 14 days | 81.82/72.73 | 85.71/80 | 13C-UBT 5–7 weeks after the end of treatment. |
Cindoruk et al.17 | Turkey | 124 (62/62) | histology | S. boulardii | (lansoprazole 30 mg bid + Clarithromycin 500 mg bid + amoxicillin 1 g bid) × 14 days + (probiotics or placebo) × 14 days | 70.97/59.68 | 70.97/59.68 | 13C-UBT six weeks after the end of treatment. |
Manfredi et al.19 | Italy | 149 (73/76) | 13C-UBT or SAT | Lactobacilli and Bifidobacteria | (esomeprazole 20 mg bid + amoxicillin 1 g bid) × first five days + (esomeprazole 20 mg bid + clarithromycin 500 mg bid + tinidazole 500 mg bid) × next five days + (probiotics or placebo) × 10 days (total) | 89.04/88.16 | 92.86/94.37 | SAT 8–10 weeks after the end of treatment. |
Myllyluoma et al.20 | Finland | 47 (23/24) | 13C-UBT | Lactobacillus rhamnosus, L. rhamnosus, Bifidobacterium breve and Propionibacterium freudenreichii) | (lansoprazole 30 mg bid + Clarithromycin 500 mg bid + amoxicillin 1 g bid) × seven days + (probiotics or placebo) × 28 days | 91.30/79.17 | 91.30/79.17 | 13C-UBT four weeks after the end of treatment. |
Armuzzi et al.24 | Italy | 60 (30/30) | 13C-UBT | Lactobacillus GG | (rabeprazole 20 mg bid + Clarithromycin 500 mg bid + tinidazole 500 mg bid) × seven days + (probiotics or placebo) × 14 days | 83.33/80 | 83.33/80 | 13C-UBT six weeks after the end of treatment. |
Shavakhi et al.23 | Iran | 180 (90/90) | RUT or histology | Lactobacillus and Bifidobacterium | (omeprazole 20 mg bid + Clarithromycin 500 mg bid + amoxicillin 1 g bid + bismuth 240 mg bid) × 14 days + (probiotics or placebo) × 14 days | 76.67/81.11 | 82.14/84.88 | 13C-UBT four weeks after the end of treatment. |
